Vaccines for preventing herpes zoster in older adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Gagliardi, Anna Mz ^a   Andriolo, Brenda Ng ^b   Torloni, Maria R ^b   Soares, Bernardo Go ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Cochrane Centre   (Brazil)

^c Dermatologist at the STD AIDS Reference and Train   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; PLACEBO; SODIUM CHLORIDE; VARICELLA ZOSTER VACCINE;

ATTRIBUTABLE RISK; CAUCASIAN; CHICKENPOX; CINAHL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EMBASE; FATIGUE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOMA; HERPES ZOSTER; HUMAN; INCIDENCE; INCOME; INJECTION PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE VESICLE; INTERVENTION STUDY; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MYALGIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VACCINATION; VARICELLA ZOSTER VIRUS; AGED; MIDDLE AGED;

AGED; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED;

EID: 84961928051     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008858.pub3     Document Type: Review

References (86)

1. Berger R, Trannoy E, Holländer G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases 1998;178(Suppl 1):99-103. [0022-1899/98/78S1-0022$02.00]
2. Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6. [PII: S0264-410X (99) 00510-1]
3. Chlibek R, Bayas JM, Collins H, Pinta MLR, Ledent E, Johann F, et al. Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. Journal of Infectious Diseases 2013;208:1953-61.
4. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014;32(15):1745-53.
5. Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. Vaccine 2015;33(6):789-95. [MEDLINE: PMID: 25555381]
6. Diez-Domingo J, Weinke T, Kieninger-Baum D, Eymin C, Thomas S, Sadorged C. A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged ≥ 50 years. European Geriatric Medicine 2013;4(Suppl):81-141.
7. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology 2008;15(2):314-9. [DOI: 10.1128/CVI.00310-07]
8. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine 2015;372(22):2087-96. [DOI: 10.1056/NEJMoa1501184]
9. Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000;18(25):2915-20. [PUBMED: 10812235]
10. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010;28(25):4204-9. [DOI: 10.1016/j.vaccine.2010.04.003]
11. Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Human Vaccines 2011;7(11):1130-6.
12. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases 2008;197:825-35. [DOI: 10.1086/528696]
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005;352(22):2271-84. [PUBMED: 15930418]
14. Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WWB, Zhang JH, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal American Geriatrics Society 2010;58(9):1634-41. [DOI: 10.1111/j.1532-5415.2010.03021.x]
15. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases 2012;55(10):1320-8. [DOI: 10.1093/cid/cis638]
16. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of herpes zoster vaccine in the shingles prevention study a randomized trial. Annals of Internal Medicine 2010;152(9):545-54. [PUBMED: 20439572]
17. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caufield MJ, et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. Journal of Infectious Diseases 2009;200(7):1068-77. [DOI: 10.1086/605611]
18. Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine 2007;25:1877-83.
19. Vermeulen JN, Lange JMA, Tyring SK, Peters PH, Nunez M, Poland G, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine 2012;30(5):904-10.
20. Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years. A randomized study of a single dose vs. two different two-dose schedules. Human Vaccines & Immunotherapeutics 2013;9(4):1-7.
21. Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or Inactivated VZV vaccine in elderly adults. Viral Immunology 1994;7(1):31-6. [PUBMED: 7986334]
22. Hayward AR, Buda K, Jones M, White C Jo, Levin MJ. Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology 1996;9(4):241-5. [PUBMED: 8978020]
23. Irwin MR, Olmstead R, Oxman MN. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. Journal American Geriatrics Society 2007;55(4):511-7. [DOI: 10.1111/j.532-5415.2007.01109.x]
24. Kerzner B, Murray AV, Gheng E, Ifle R, Harvey PR, Tomlinson M, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. Journal of the American Geriatrics Society 2007;55(10):1499-507. [DOI: 10.1111/j.1532-5415.2007.01397.x]
25. Leroux-Roels I, Leroux-Roels G, Frédéric Clement F, Vandepapelière P, Vassilev V, Ledent E, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. Journal of Infectious Diseases 2012;206:1280-90.
26. Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007;25:2139-44. [DOI: 10.1016/j.vaccine.2006.11.011]
27. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weingerg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 2007;25(41):7087-93. [PUBMED: 17766015]
28. 'A double-blind, randomised, placebo-controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunisation with V212/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers'. Ongoing study March 2009.
29. 'Efficacy, safety, and immunogenicity study of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged ≥ 50 years'. Ongoing study August 2010.
30. 'Efficacy, safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged >= 70 years'. Ongoing study August 2010.
31. 'A partially blinded randomised clinical trial to study the immunogenicity and safety of intradermal administration of ZOSTAVAX™ (V211)'. Ongoing study September 2011.
32. 'A phase III double-blinded, randomised, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ made with an alternative manufacturing process (AMP)'. Ongoing study April 2012.
33. 'Open-label study to evaluate the safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged ≥ 50 years'. Ongoing study March 2013.
34. 'Safety and immunogenicity study of GSK Biologicals' herpes zoster subunit (HZ/su) vaccine GSK1437173A when administered subcutaneously vs. intramuscularly in adults aged ≥ 50 years'. Ongoing study June 2013.
35. 'Consistency, immunogenicity and safety study of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults ≥ 50 years of age'. Ongoing study August 2014.
36. 'A comparison of the immunogenicity and descriptive safety of a live attenuated herpes zoster vaccine and the GSK herpes zoster recombinant HZ/su candidate vaccine in 50 to 59 year old and 70 to 85 year old vaccine recipients'. Ongoing study May 2014.
37. 'A phase III, double-blind, lot-to-lot consistency clinical trial to evaluate the safety, tolerability and immunogenicity of V212 in healthy adults'. Ongoing study July 2014.
38. 'Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50 years and older'. Ongoing study November 2015.
39. Arvin A. Ageing, immunity, and the varicella-zoster virus. New England Journal of Medicine 2005;352(22):2266-7. [PUBMED: 15930416]
40. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. Journal of Immunology 1986;137(4):1346-51. [PMID: 3016094]
41. Arvin AM. Varicella-zoster virus. Clinical Microbiology Reviews 1996;9(3):361-81. [PUBMED: 8809466]
42. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
43. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, el al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opinion on Biological Therapy 2004;4:1129-38. [PMID: 15268679]
44. Cho JW, Shin DH, Lee KS. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. Journal of Dermatological Science 2007;45(3):213-5. [PUBMED: 17204399]
45. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. Journal of Clinical Virology 2010;47(4):325-9. [PUBMED: 20181512]
46. Cohen JI, Straus SE, Arvin AM. Varicella-zoster virus replication, pathogenesis, and management. In: Knipe DM editor(s). Fields' Virology. 5th Edition. Philadelphia: Lippincott Williams and Wilkins, 2007:2773-818.
47. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. Journal of Pain 2004;5(6):344-56. [DOI: 10.1016/j.jpain.2004.06.001]
48. Dolin R, Reichman RC, Mazur MH, Whitkey RJ. Herpes zoster-varicella infections in immunosuppressed patients. Annals of Internal Medicine 1978;89(3):375-88. [DOI: 10.7326/0003-4819-89-3-375]
49. Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009;142(3):209-17. [PUBMED: 19195785]
50. Gatti A, Pica F, Boccia MT, De Antoni F, Sabato AF, Volpi A. No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. Journal of Medical Virology 2010;82(6):1007-11. [PUBMED: 20419815]
51. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella zoster virus. New England Journal of Medicine 2000;342(9):635-45. [PUBMED: 10699164]
52. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. New England Journal of Medicine 2002;347(5):340-6. [12151472]
53. McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
54. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006;129:174-81. [PUBMED: 16424429]
55. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schünemann H. An emerging consensus on grading recommendations?. ACP Journal Club 2006;144:A8-9. [PUBMED: 16388549]
56. Haanpaa M, Nurmikko T, Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scandinavian Journal of Infectious Diseases 2002;34:112-4. [PUBMED: 11928840]
57. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008;36(3):226-30. [PUBMED: 18454342]
58. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. Archives of Dermatology 2008;144(5):603-8. [PUBMED: 18490586]
59. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.) 2003;327(7414):557-60. [PUBMED: 12958120]
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Hope-Simpson E. The nature of herpes zoster: a long-term study and a new hypothesis. Proceedings of the Royal Society of Medicine 1965;58(1):9-12. [PMC 1898279]
62. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and post herpetic neuralgia in older adults. Annals of Internal Medicine 2006;145(5):317-25. [PUBMED: 16954357]
63. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Dermato-Venereologica 2009;89(6):612-6. [PUBMED: 19997693]
64. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clinical Infectious Diseases 2004;39:342-8. [PUBMED: 15307000]
65. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molinacortex. Journal of Immunology 1991;146:431-7. [PMID: 1987271]
66. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Medicine 2013;10(4):1-11. [PUBMED: 23585738]
67. Latour J, Abraira V, Cabello JB, López Sánchez J. Investigation methods in clinical cardiology (IV) clinical measurements in cardiology: validity and errors of measurement. Revista Española de Cardiología 1997;50(2):117-28. [PUBMED: 9091999]
68. Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: a case-control study of adverse events in a national database. Journal of Drugs in Dermatology 2015;14(7):681-4. [PUBMED: 26151783]
69. Lee BW. Review of varicella zoster soroepidemiology in India and South-East Asia. Tropical Medicine & International Health 1998;3(11):886-90. [DOI: 10.1046/j.1365-3156.1998.00316.x; PUBMED: 9855401]
70. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995;45(Suppl 8):52-3. [PUBMED: 8545021]
72. Moffat J, Ku CC, Zerboni L, Sommer M, Arvin A. Pathogenesis and the disease consequences of primary infection. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al. editor(s). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007. [PUBMED: 21348076]
73. Partridge DG, McKendrick MW. The treatment of varicella-zoster virus infection and its complications. Expert Opinion on Pharmacotherapy 2009;10(5):797-812. [PUBMED: 19351229]
74. Rajesh K, Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995;13(14):1263-76. [DOI: 10.1016/0264-410X(95)00011-O]
75. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
76. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clinical Infectious Diseases 2010;50(7):1000-5. [PUBMED: 20178416]
77. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clinic Proceedings 2009;84(3):274-80. [PUBMED: 19252116]
78. Sanford M, Keating GM. Zoster vaccine (Zostavax®) a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs and Aging 2010;27(2):159-76. [1170-229X/10/0002-0159/$49.95/0]
79. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. Herpes zoster pain and discomfort on functional status and quality of life in older adults. Clinical Journal of Pain 2007;23(6):490-6. [PUBMED: 17575488]
80. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. Journal of Infectious Diseases 2008;197(Suppl):207-15. [PUBMED: 18419399]
81. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
82. Sutradhar SC, Wang WWB, Schlienger K, Stek JE, Xu J, Chan ISF, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clinical and Vaccine Immunology 2009;16:646-52. [DOI: 10.1128/CVI.00407-08]
83. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infectious Diseases 2004;4(1):26-33. [PUBMED: 14720565]
84. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. Journal of the American Osteopathic Association 2007;107(Suppl 1):2-7. [PUBMED: 17488884]
85. Gagliardi AMZ, Gomes SBN, Torloni MR, Soares BGO. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD008858]
86. Gagliardi AMZ, Silva BNG, Torloni MR, Soares BGO. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD008858.pub2]